RESUMEN
The reactions of the medicinal gold(I) compound auranofin and its close analogues with vasopressin and the diselenide analogue were comparatively investigated by LC-electrospray MS/MS. Evidence is gained of the possible cleavage of the S-S and Se-Se bridges induced by Au(I). Notably, we found that, in the absence of reducing agents, the sulfur and selenium atoms are metallated only at high temperature (70 °C) with the preferential binding of gold to selenium. The reaction with the S-S bridge can take place at physiological temperature (37 °C) under reducing conditions. The implications of these results are discussed in the general frame of the reactivity of biologically relevant soft Lewis acids with peptides and proteins.
Asunto(s)
Neurofisinas/antagonistas & inhibidores , Compuestos Orgánicos de Oro/farmacología , Compuestos de Organoselenio/farmacología , Precursores de Proteínas/antagonistas & inhibidores , Vasopresinas/antagonistas & inhibidores , Humanos , Neurofisinas/metabolismo , Compuestos Orgánicos de Oro/química , Compuestos de Organoselenio/química , Precursores de Proteínas/metabolismo , Vasopresinas/metabolismoRESUMEN
AIMS: To understand mechanisms underlying vasopressin hypersecretion in stroke and its association with brain injury, we investigated effects of blocking aquaporin 4 (AQP4) in the supraoptic nucleus (SON) on vasopressin neuronal activity and cerebral injuries in male rats of unilateral middle cerebral artery occlusion (MCAO). MAIN METHODS: Establishing MCAO model without or with microinjection of TGN-020 into the SON, performing Western blots and immunohistochemistry and analyzing the expression levels and spatial distribution of functional proteins in the SON and/or the cerebral cortex. KEY FINDINGS: MCAO increased plasma vasopressin levels, caused neurological damage and increased glycogen synthase kinase 3ß (GSK-3ß) in the SON and the cortex of MCAO side. In the SON, MCAO significantly increased c-Fos in vasopressin neurons and astrocytic somata in the ventral glial lamina. MCAO significantly reduced glial fibrillary acidic protein (GFAP) and AQP4 around vasopressin neurons, which accompanied separation of GFAP from AQP4. By contrast, blocking AQP4 by microinjection of TGN-020 into the SON blocked MCAO-evoked GSK-3ß increase as well as the reduction of AQP4 relative to GFAP around vasopressin neurons in the SON. In the cortex, TGN-020 in the SON also blocked MCAO-evoked increase in GSK-3ß while reduced neurological damages. SIGNIFICANCE: These findings indicate that MCAO disrupts interactions of GFAP with AQP4 in astrocytic processes in the SON, which increases vasopressin neuronal activity. Blocking AQP4 in the SON can block abnormal activation of vasopressin neurons and alleviate ischemic brain injury, which provides novel targets for alleviating ischemic brain injury.
Asunto(s)
Lesiones Encefálicas/metabolismo , Accidente Cerebrovascular Isquémico/metabolismo , Neuronas/metabolismo , Niacinamida/análogos & derivados , Núcleo Supraóptico/metabolismo , Tiadiazoles/administración & dosificación , Vasopresinas/metabolismo , Animales , Lesiones Encefálicas/tratamiento farmacológico , Accidente Cerebrovascular Isquémico/tratamiento farmacológico , Masculino , Microinyecciones/métodos , Neuronas/efectos de los fármacos , Niacinamida/administración & dosificación , Ratas , Ratas Wistar , Núcleo Supraóptico/efectos de los fármacos , Vasopresinas/antagonistas & inhibidoresRESUMEN
Subjects with obesity frequently have elevated serum vasopressin levels, noted by measuring the stable analog, copeptin. Vasopressin acts primarily to reabsorb water via urinary concentration. However, fat is also a source of metabolic water, raising the possibility that vasopressin might have a role in fat accumulation. Fructose has also been reported to stimulate vasopressin. Here, we tested the hypothesis that fructose-induced metabolic syndrome is mediated by vasopressin. Orally administered fructose, glucose, or high-fructose corn syrup increased vasopressin (copeptin) concentrations and was mediated by fructokinase, an enzyme specific for fructose metabolism. Suppressing vasopressin with hydration both prevented and ameliorated fructose-induced metabolic syndrome. The vasopressin effects were mediated by the vasopressin 1b receptor (V1bR), as V1bR-KO mice were completely protected, whereas V1a-KO mice paradoxically showed worse metabolic syndrome. The mechanism is likely mediated in part by de novo expression of V1bR in the liver that amplifies fructokinase expression in response to fructose. Thus, our studies document a role for vasopressin in water conservation via the accumulation of fat as a source of metabolic water. Clinically, they also suggest that increased water intake may be a beneficial way to both prevent or treat metabolic syndrome.
Asunto(s)
Fructosa/metabolismo , Síndrome Metabólico/metabolismo , Receptores de Vasopresinas/metabolismo , Vasopresinas/metabolismo , Animales , Modelos Animales de Enfermedad , Ingestión de Líquidos/fisiología , Fructoquinasas/metabolismo , Fructosa/administración & dosificación , Células Hep G2 , Humanos , Hígado/metabolismo , Masculino , Síndrome Metabólico/inducido químicamente , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Receptores de Vasopresinas/deficiencia , Receptores de Vasopresinas/genética , Vasopresinas/antagonistas & inhibidores , Vasopresinas/biosíntesisRESUMEN
Cone snails produce a fast-acting and often paralyzing venom, largely dominated by disulfide-rich conotoxins targeting ion channels. Although disulfide-poor conopeptides are usually minor components of cone snail venoms, their ability to target key membrane receptors such as GPCRs make them highly valuable as drug lead compounds. From the venom gland transcriptome of Conus miliaris, we report here on the discovery and characterization of two conopressins, which are nonapeptide ligands of the vasopressin/oxytocin receptor family. These novel sequence variants show unusual features, including a charge inversion at the critical position 8, with an aspartate instead of a highly conserved lysine or arginine residue. Both the amidated and acid C-terminal analogues were synthesized, followed by pharmacological characterization on human and zebrafish receptors and structural investigation by NMR. Whereas conopressin-M1 showed weak and only partial agonist activity at hV1bR (amidated form only) and ZFV1a1R (both amidated and acid form), both conopressin-M2 analogues acted as full agonists at the ZFV2 receptor with low micromolar affinity. Together with the NMR structures of amidated conopressins-M1, -M2 and -G, this study provides novel structure-activity relationship information that may help in the design of more selective ligands.
Asunto(s)
Conotoxinas/química , Conotoxinas/farmacología , Caracol Conus/química , Secuencia de Aminoácidos , Animales , Conotoxinas/síntesis química , Disulfuros/química , Disulfuros/farmacología , Humanos , Conformación Molecular , Venenos de Moluscos/química , Neurofisinas/antagonistas & inhibidores , Precursores de Proteínas/antagonistas & inhibidores , Receptores de Oxitocina/efectos de los fármacos , Receptores de Vasopresinas/efectos de los fármacos , Relación Estructura-Actividad , Transcriptoma , Vasopresinas/antagonistas & inhibidores , Pez CebraRESUMEN
BACKGROUND: Vasopressin stimulates cyst growth in autosomal dominant polycystic kidney disease (ADPKD) and is a key therapeutic target. Evaluation of high water intake as an alternative to pharmacological vasopressin blockade is supported by patients. However feasibility, safety and adherence-promoting strategies required to deliver this remain unknown. AIMS: Assess the feasibility of a definitive randomized high water intake trial in ADPKD. METHODS: In this prospective open-label randomized trial, adult ADPKD patients with eGFR ≥ 20 ml/min/1.73 m2 were randomized to prescribed high water (HW) intake targeting urine osmolality (UOsm) ≤270 mOsm/kg, or ad libitum (AW) intake (UOsm >300 mOsm/kg). Self-management strategies including home-monitoring of urine-specific gravity (USG) were employed to promote adherence. RESULTS: We enrolled 42 participants, baseline median eGFR (HW 68.4 [interquartile range (IQR) 35.9-107.2] vs. AW 75.8 [IQR 59.0-111.0 ml/min/1.73 m2, P = 0.22) and UOsm (HW 353 [IQR 190-438] vs. AW 350 [IQR 240-452] mOsm/kg, P = 0.71) were similar between groups. After 8 weeks, 67% in the HW vs. 24% in AW group achieved UOsm ≤270 mOsm/kg, P = 0.001. HW group achieved lower UOsm (194 [IQR 190-438] vs. 379 [IQR 235-503] mOsm/kg, P = 0.01) and higher urine volumes (3155 [IQR 2270-4295] vs. 1920 [IQR 1670-2960] ml/day, P = 0.02). Two cases of hyponatraemia occurred in HW group. No acute GFR effects were detected. In total 79% (519/672) of USG were submitted and 90% (468/519) were within target. Overall, 17% withdrew during the study. CONCLUSION: DRINK demonstrated successful recruitment and adherence leading to separation between treatment arms in primary outcomes. These findings suggest a definitive trial assessing the impact of high water on kidney disease progression in ADPKD is feasible.
Asunto(s)
Ingestión de Líquidos , Riñón Poliquístico Autosómico Dominante , Agua , Adulto , Estudios de Factibilidad , Femenino , Tasa de Filtración Glomerular , Humanos , Masculino , Persona de Mediana Edad , Riñón Poliquístico Autosómico Dominante/metabolismo , Riñón Poliquístico Autosómico Dominante/fisiopatología , Riñón Poliquístico Autosómico Dominante/terapia , Estudios Prospectivos , Resultado del Tratamiento , Vasopresinas/antagonistas & inhibidores , Adulto JovenRESUMEN
Modulating neurohormonal imbalance is the cornerstone of successful therapy in patients with chronic heart failure with reduced ejection fraction (HFrEF). Plasma arginine vasopressin (AVP) levels are elevated in HFrEF and may contribute to disease progression by excess signaling at either the V1a or V2 receptors. The effects of V1a receptor antagonism are almost completely unexplored, but V1a signaling is closely related to that for angiotensin II and blocking that receptor deserves further study. Interfering with V2 signaling causes free water diuresis and improves congestion without worsening renal function when added to loop diuretics but alone did not improve outcomes when carried into the post-acute phase in one large study. Outcomes in chronic HFrEF are quite good while outcomes in acute HF remain poor. Therefore, further study of V2 or combined V1/V2 blockade of the effects of AVP would most likely yield positive results in patients with acute HF, perhaps especially as alternative, not adjunctive therapy to loop diuretics.
Asunto(s)
Antagonistas de los Receptores de Hormonas Antidiuréticas/uso terapéutico , Insuficiencia Cardíaca/tratamiento farmacológico , Neurofisinas/antagonistas & inhibidores , Precursores de Proteínas/antagonistas & inhibidores , Receptores de Vasopresinas/sangre , Vasopresinas/antagonistas & inhibidores , Enfermedad Crónica , Progresión de la Enfermedad , Femenino , Insuficiencia Cardíaca/sangre , Insuficiencia Cardíaca/fisiopatología , Humanos , Masculino , Neurofisinas/sangre , Precursores de Proteínas/sangre , Inhibidores del Simportador de Cloruro Sódico y Cloruro Potásico/uso terapéutico , Volumen Sistólico , Vasopresinas/sangreRESUMEN
ADH is a hormone secreted by neurohypophysis that plays different roles based on the target organ. At the renal level, this peptide is capable of causing electrolyte-free water absorption, thus playing a key role in the hydro-electrolytic balance. There are pathologies and disorders that jeopardize this balance and, in this field, ADH receptor inhibitors such as Vaptans could play a key role. By inhibiting the activation pathway of vasopressin, they are potentially useful in euvolemic and hypervolemic hypotonic hyponatremia. However, clinical trials in heart failure have not given favourable results on clinical outcomes. Even in SIADH, despite their wide use, there is no agreement by experts on their use. Since vaptans inhibit the cAMP pathway in tubular cells, their use has been proposed to inhibit cystogenesis. A clinical trial has shown favourable effects on ADPKD progression. Because vaptans have been shown to be effective in models of renal cysts disorders other than ADPKD, their use has been proposed in diseases such as nephronophthisis and recessive autosomal polycystic disease. Other possible uses of vaptans could be in kidney transplantation and cardiorenal syndrome. Due to the activity of ADH in coagulation and haemostasis, ADH's activation pathway by Desmopressin Acetate could be a useful strategy to reduce the risk of bleeding in biopsies in patients with haemorrhagic risk.
Asunto(s)
Antagonistas de los Receptores de Hormonas Antidiuréticas/uso terapéutico , Enfermedades Renales/tratamiento farmacológico , Terapia Molecular Dirigida , Neurofisinas/agonistas , Neurofisinas/antagonistas & inhibidores , Precursores de Proteínas/agonistas , Precursores de Proteínas/antagonistas & inhibidores , Receptores de Vasopresinas/efectos de los fármacos , Vasopresinas/agonistas , Vasopresinas/antagonistas & inhibidores , Desequilibrio Hidroelectrolítico/tratamiento farmacológico , Antagonistas de los Receptores de Hormonas Antidiuréticas/farmacología , Cadáver , AMP Cíclico/fisiología , Predicción , Humanos , Hiponatremia/tratamiento farmacológico , Hiponatremia/fisiopatología , Enfermedades Renales/fisiopatología , Enfermedades Renales Quísticas/tratamiento farmacológico , Trasplante de Riñón , Túbulos Renales Colectores/efectos de los fármacos , Túbulos Renales Colectores/fisiología , Neurofisinas/fisiología , Riñón Poliquístico Autosómico Dominante/tratamiento farmacológico , Riñón Poliquístico Autosómico Dominante/fisiopatología , Precursores de Proteínas/fisiología , Receptores de Vasopresinas/agonistas , Sistemas de Mensajero Secundario/efectos de los fármacos , Donantes de Tejidos , Vasopresinas/fisiologíaRESUMEN
BACKGROUND: Arginine vasopressin (VP) has been implicated in a number of neuropsychiatric disorders with an emphasis on situations where stress increased the severity of the disorder. Based on this hypothesized role for VP in neuropsychiatric disorders, much research is currently being undertaken in humans and animals to test VP as a target for treatment of a number of these disorders including alcohol abuse. OBJECTIVES: To provide a summary of the literature regarding the role of VP in alcohol- and stress-related behaviors including the use of drugs that target VP in clinical trials. RESULTS: Changes in various components of the VP system occur with alcohol and stress. Manipulating VP or its receptors can alter alcohol- and stress-related behaviors including tolerance to alcohol, alcohol drinking, and anxiety-like behavior. Finally, the hypothalamic-pituitary-adrenal axis response to alcohol is also altered by manipulating the VP system. However, clinical trials of VP antagonists have had mixed results. CONCLUSIONS: A review of VP's involvement in alcohol's actions demonstrates that there is much to be learned about brain regions involved in VP-mediated effects on behavior. Thus, future work should focus on elucidating relevant brain regions. By using previous knowledge of the actions of VP and determining the brain regions and/or systems involved in its different behavioral effects, it may be possible to identify a specific receptor subtype target, drug treatment combination, or specific clinical contexts that may point toward a more successful treatment.
Asunto(s)
Consumo de Bebidas Alcohólicas/metabolismo , Alcoholismo/metabolismo , Etanol/administración & dosificación , Neurofisinas/metabolismo , Precursores de Proteínas/metabolismo , Vasopresinas/metabolismo , Consumo de Bebidas Alcohólicas/tratamiento farmacológico , Consumo de Bebidas Alcohólicas/psicología , Alcoholismo/tratamiento farmacológico , Alcoholismo/psicología , Animales , Antagonistas de los Receptores de Hormonas Antidiuréticas/farmacología , Ansiedad/tratamiento farmacológico , Ansiedad/metabolismo , Ansiedad/psicología , Arginina Vasopresina/antagonistas & inhibidores , Arginina Vasopresina/metabolismo , Etanol/toxicidad , Humanos , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Sistema Hipotálamo-Hipofisario/metabolismo , Neurofisinas/antagonistas & inhibidores , Sistema Hipófiso-Suprarrenal/efectos de los fármacos , Sistema Hipófiso-Suprarrenal/metabolismo , Precursores de Proteínas/antagonistas & inhibidores , Estrés Psicológico/tratamiento farmacológico , Estrés Psicológico/metabolismo , Estrés Psicológico/psicología , Vasopresinas/antagonistas & inhibidoresRESUMEN
Social play is a highly rewarding behavior displayed mostly during the juvenile period. We recently showed that vasopressin V1a receptor (V1aR) blockade in the lateral septum (LS) enhances social play in male juvenile rats, but reduces it in females. Here, we determined whether the LS-AVP system modulates dopamine (DA) and/or norepinephrine (NE) neurotransmission in the LS to regulate social play behavior in sex-specific ways. Using microdialysis combined with retrodialysis, we demonstrated that both LS-AVP administration and social play exposure increased extracellular LS-DA release in females, but not in males. Pharmacological blockade of LS-DA receptors reduced social play in both sexes, but required a higher dose in females. This suggests that baseline LS-DA release is sufficient for social play in males, while increased LS-DA release is necessary for social play in females. Administration of a V1aR antagonist into the LS inhibited the social play-induced increase in extracellular LS-DA release in females. Furthermore, co-administration of the DA agonist apomorphine prevented the LS-V1aR blockade-induced decrease in social play in females. This suggests that LS-V1aR blockade reduces social play in females by dampening the rise in LS-DA release. Extracellular LS-NE release was enhanced in response to pharmacological manipulations of the LS-AVP system and to social play in males and/or females, but pharmacological blockade or stimulation of LS-NE receptors did not alter social play in either sex. Overall, we define a mechanism by which the LS-AVP system alters LS-DA neurotransmission differently in males than females resulting in the sex-specific regulation of juvenile social play behavior.
Asunto(s)
Dopamina/fisiología , Norepinefrina/fisiología , Recompensa , Conducta Social , Vasopresinas/metabolismo , Animales , Dopamina/metabolismo , Femenino , Masculino , Microdiálisis , Norepinefrina/metabolismo , Juego e Implementos de Juego/psicología , Ratas , Ratas Wistar , Receptores de Vasopresinas/agonistas , Tabique del Cerebro/efectos de los fármacos , Caracteres Sexuales , Vasopresinas/antagonistas & inhibidores , Vasopresinas/efectos de los fármacosRESUMEN
BACKGROUND: Ethanol (EtOH)-evoked oxidative stress, which contributes to myocardial dysfunction in proestrus rats, is mediated by increases in NADPH oxidase (Nox) activity, malondialdehyde (MDA), and ERK1/2 phosphorylation. Whether these biochemical responses, which are triggered by alcohol-derived acetaldehyde in noncardiac tissues, occur in proestrus rats' hearts remains unknown. Therefore, we elucidated the roles of alcohol dehydrogenase (ADH), cytochrome P4502E1 (CYP2E1), and catalase, which catalyze alcohol oxidation to acetaldehyde, in these alcohol-evoked biochemical and hemodynamic responses in proestrus rats. METHODS: Conscious proestrus rats prepared for measurements of left ventricular (LV) function and blood pressure (BP) received EtOH (1.5 g/kg, intravenous [i.v.] infusion over 30 minutes) or saline 30 minutes after an ADH and CYP2E1 inhibitor, 4-methylpyrazole (4-MP) (82 mg/kg, intraperitoneal), a catalase inhibitor, 3-AT (0.5 g/kg, i.v.), their combination, or vehicle. LV function and BP were monitored for additional 60 minutes after EtOH or saline infusion before collecting the hearts for ex vivo measurements of LV reactive oxygen species (ROS), Nox activity, MDA, and ERK1/2 phosphorylation. RESULTS: EtOH reduced LV function (dP/dtmax and LV developed pressure) and BP, and increased cardiac Nox activity, ROS and MDA levels, and ERK1/2 phosphorylation. Either inhibitor partially, and their combination significantly, attenuated these responses despite the substantially higher blood EtOH level, and the increased cardiac oxidative stress and reduced BP caused by 3-AT alone or with 4-MP. The inhibitors reduced cardiac MDA level and reversed EtOH effect on cardiac and plasma MDA. CONCLUSIONS: EtOH oxidative metabolism plays a pivotal role in the EtOH-evoked LV oxidative stress and dysfunction in proestrus rats. Notably, catalase inhibition (3-AT) caused cardiac oxidative stress and hypotension.
Asunto(s)
Cardiomiopatías/inducido químicamente , Cardiomiopatías/prevención & control , Catalasa/antagonistas & inhibidores , Depresores del Sistema Nervioso Central/toxicidad , Inhibidores Enzimáticos/uso terapéutico , Etanol/toxicidad , Neurofisinas/antagonistas & inhibidores , Estrés Oxidativo/efectos de los fármacos , Precursores de Proteínas/antagonistas & inhibidores , Vasopresinas/antagonistas & inhibidores , Amitrol (Herbicida)/farmacología , Animales , Presión Sanguínea/efectos de los fármacos , Cardiomiopatías/fisiopatología , Depresores del Sistema Nervioso Central/antagonistas & inhibidores , Depresores del Sistema Nervioso Central/sangre , Etanol/antagonistas & inhibidores , Etanol/sangre , Femenino , Fomepizol , Proestro , Pirazoles/uso terapéutico , Ratas , Ratas Sprague-Dawley , Función Ventricular IzquierdaRESUMEN
Catecholamines trigger proximal tubular fluid retention and reduce renal excretion of solute-free water. In advanced cirrhosis, non-osmotic hypersecretion of vasopressin (antidiuretic hormone or ADH) is considered the cause of dilutional hyponatraemia, but ADH V2 receptor antagonists are not beneficial in long-term treatment of ascites. To test the hypothesis that water retention in experimental ascitic cirrhosis might depend primarily on adrenergic hyper-function, hormonal status, renal function and tubular free-water reabsorption (TFWR) were assessed in six groups of rats with ascitic cirrhosis: rats with cirrhosis due to 13-week CCl4 (carbon tetrachloride) administration (group G1); cirrhotic rats receiving daily diuretics (0.5 mg/kg furosemide plus 2 mg/kg K(+)-canrenoate) from the 11th to the 13th week of CCl4 (G2), diuretics associated with guanfacine oral prodrug (α2A-adrenergic receptor agonist and sympatholytic agent) at 2 (G3), 7 (G4) or 10 (G5) mg/kg, or with SSP-004240F1 (V2 receptor antagonist) at 1 mg/kg (G6). Natriuresis was lower in G1 than in G2, G4 and G6 (all P<0.05). Guanfacine, added to diuretics (i.e. G3 compared with G2), reduced serum noradrenaline from 423±22 to 211±41 ng/l (P<0.05), plasma renin activity (PRA) from 35±8 to 9±2 ng/ml/h (P<0.05) and TFWR from 45±8 to 20±6 µl/min (P<0.01). TFWR correlated with plasma aldosterone (r=0.51, P<0.01) and urinary potassium excretion (r=0.90, P<0.001). In ascitic cirrhosis, reduced volaemia, use of diuretics (especially furosemide) and adrenergic hyper-function cause tubular retention of water. Suitable doses of sympatholytic agents are effective aquaretics.
Asunto(s)
Ascitis/fisiopatología , Cirrosis Hepática Experimental/fisiopatología , Vasopresinas/fisiología , Animales , Ascitis/tratamiento farmacológico , Ascitis/etiología , Ácido Canrenoico/farmacología , Diuréticos/farmacología , Furosemida/farmacología , Guanfacina/farmacología , Hiponatremia/etiología , Hiponatremia/fisiopatología , Cirrosis Hepática Experimental/complicaciones , Masculino , Natriuresis/efectos de los fármacos , Natriuresis/fisiología , Norepinefrina/sangre , Ratas , Ratas Wistar , Vasopresinas/antagonistas & inhibidoresRESUMEN
Cirrhosis is characterized by systemic and splanchnic vasodilation that leads to excessive nonosmotic secretion of vasopressin (antidiuretic hormone). Hyponatremia is a common electrolyte abnormality in advanced liver disease that results from the impaired ability of the kidney to excrete solute-free water that leads to "dilutional" hyponatremia-water retention disproportionate to the retention of sodium. Hyponatremia in liver diseases carries the prognostic burden, correlates with the severity of cirrhosis, and, in recent studies, has also been implicated in the pathogenesis of hepatic encephalopathy. The current treatment options are limited to conventional therapies like fluid restriction, and the outcomes are unsatisfactory. Although currently available vasopressin (V2 receptors) antagonists have been shown to increase serum sodium concentrations and improve ascites control, their role in the treatment of hyponatremia in liver disease patients remains questionable because of adverse effect profiles, high cost, and poor data on long-term mortality benefits. More information is needed to argue the benefits vs risks of short-term use of vaptans for correction of hyponatremia especially just hours-to-days before liver transplant.
Asunto(s)
Hiponatremia/etiología , Hiponatremia/terapia , Cirrosis Hepática/complicaciones , Vasopresinas/antagonistas & inhibidores , Quimioterapia Combinada , Femenino , Humanos , Hiponatremia/fisiopatología , Cirrosis Hepática/patología , Cirrosis Hepática/fisiopatología , Masculino , Pronóstico , Medición de Riesgo , Índice de Severidad de la Enfermedad , Tasa de Supervivencia , Resultado del Tratamiento , Vasopresinas/uso terapéuticoRESUMEN
Rapid correction of severe hyponatremia carries the risk of osmotic demyelination. Two recently introduced methods of correction of hyponatremia have diametrically opposite effects on aquaresis. Inhibitors of vasopressin V2 receptor (vaptans) lead to the production of dilute urine, whereas infusion of desmopressin causes urinary concentration. Identification of the category of hyponatremia that will benefit from one or the other treatment is critical. In general, vaptans are effective in hyponatremias presenting with concentrated urine and, with the exception of hypovolemic hyponatremia, can be used as their primary treatment. Desmopressin is effective in hyponatremias presenting with dilute urine or developing urinary dilution after saline infusion. In this setting, desmopressin infusion helps prevent overcorrection of the hyponatremia. Monitoring of the changes in serum sodium concentration as a guide to treatment changes is imperative regardless of the initial treatment of severe hyponatremia.
Asunto(s)
Desamino Arginina Vasopresina/administración & dosificación , Hiponatremia/tratamiento farmacológico , Solución Salina Hipertónica/administración & dosificación , Índice de Severidad de la Enfermedad , Vasopresinas/antagonistas & inhibidores , Animales , Manejo de la Enfermedad , Humanos , Hiponatremia/sangre , Infusiones Intravenosas , Vasopresinas/sangreRESUMEN
Autosomal dominant polycystic kidney disease (ADPKD), which frequently leads to end-stage renal disease, currently has no specific drug therapies. Better understanding of its pathogenesis and recent clinical trials have led to more accurate diagnosis of the disease and its manifestations, as well as to promising new approaches to treatment.
Asunto(s)
Riñón Poliquístico Autosómico Dominante/diagnóstico , Riñón Poliquístico Autosómico Dominante/terapia , Vasopresinas/antagonistas & inhibidores , Descubrimiento de Drogas , Humanos , Hipertensión/etiología , Aneurisma Intracraneal/etiología , Dolor/etiología , Riñón Poliquístico Autosómico Dominante/complicaciones , Riñón Poliquístico Autosómico Dominante/etiología , Riñón Poliquístico Autosómico Dominante/metabolismo , Transducción de Señal , Serina-Treonina Quinasas TOR/metabolismo , Infecciones Urinarias/etiología , Vasopresinas/metabolismoRESUMEN
Apelin receptors (ApelinRs) are expressed along an increasing cortico-medullary gradient in collecting ducts (CDs). We showed here that iv injection of apelin 17 (K17F) in lactating rats characterized by increases in both synthesis and release of arginine vasopressin (AVP) increased diuresis concomitantly with a significant decrease in urine osmolality and no change in Na(+) and K(+) excretion. Under these conditions, we also observed a significant decrease in apical aquaporin-2 immunolabeling in CD, with a cortico-medullary gradient, suggesting that K17F-induced diuresis could be linked to a direct action of apelin on CD. We then examined the potential cross talk between V1a AVP receptor (V1a-R), V2 AVP receptor (V2-R) and ApelinR signaling pathways in outer medullary CD (OMCD) and inner medullary CD microdissected rat CD. In OMCD, expressing the 3 receptors, K17F inhibited cAMP production and Ca(2+) influx induced by 1-desamino-8-D-arginine vasopressin a V2-R agonist. Similar effects were observed in inner medullary CD expressing only V2-R and ApelinR. In contrast, in OMCD, K17F increased by 51% the Ca(2+) influx induced by the stimulation of V1a-R by AVP in the presence of the V2-R antagonist SR121463B, possibly enhancing the physiological antagonist effect of V1a-R on V2-R. Thus, the diuretic effect of apelin is not only due to a central effect by inhibiting AVP release in the blood circulation as previously shown but also to a direct action of apelin on CD, by counteracting the antidiuretic effect of AVP occurring via V2-R.
Asunto(s)
Absorción Fisiológica/efectos de los fármacos , Péptidos y Proteínas de Señalización Intercelular/farmacología , Túbulos Renales Colectores , Receptores Acoplados a Proteínas G/fisiología , Receptores de Vasopresinas/fisiología , Vasopresinas/antagonistas & inhibidores , Agua/metabolismo , Animales , Apelina , Receptores de Apelina , Acuaporina 2/metabolismo , Diuresis/efectos de los fármacos , Túbulos Renales Colectores/efectos de los fármacos , Túbulos Renales Colectores/metabolismo , Masculino , Ratas , Ratas Sprague-Dawley , Receptor Cross-Talk/fisiología , Transducción de Señal/efectos de los fármacosRESUMEN
A regulatory effect of arginine vasopressin (AVP) on sweat water conservation has been hypothesized but not definitively evaluated. AVP-mediated insertion of sweat and salivary gland aquaporin-5 (AQP5) water channels through activation of the vasopressin type 2 receptor (V2R) remains an attractive, yet unexplored, mechanism that could result in a more concentrated sweat with resultant decreased water loss. Ten runners participated in a double-blind randomized control treadmill trial under three separate pharmacological conditions: a placebo, V2R agonist (0.2 mg desmopressin), or V2R antagonist (30 mg tolvaptan). After a familiarization trial, runners ran for 60 min at 60% of peak speed followed by a performance trial to volitional exhaustion. Outcome variables were collected at three exercise time points: baseline, after the steady-state run, and after the performance run. Body weight losses were <2% across all three trials. Significant pharmacological condition effects were noted for urine osmolality [F = 84.98; P < 0.0001] and urine sodium concentration ([Na(+)]) [F = 38.9; P < 0.0001], which verified both pharmacological activation and inhibition of the V2R at the kidney collecting duct. Plasma osmolality and [Na(+)] demonstrated significant exercise (F = 26.0 and F = 11.1; P < 0.0001) and condition (F = 5.1 and F = 3.8; P < 0.05) effects (osmolality and [Na(+)], respectively). No significant exercise or condition effects were noted for either sweat or salivary [Na(+)]. Significant exercise effects were noted for plasma [AVP] (F = 22.3; P < 0.0001), peak core temperature (F = 103.3; P < 0.0001), percent body weight change (F = 6.3; P = 0.02), plasma volume change (F = 21.8; P < 0.0001), and thirst rating (F = 78.2; P < 0.0001). Performance time was not altered between conditions (P = 0.80). In summary, AVP acting at V2R does not appear to regulate water losses from body fluids other than renal excretion during exercise.
Asunto(s)
Ejercicio Físico , Neurofisinas/metabolismo , Resistencia Física , Precursores de Proteínas/metabolismo , Receptores de Vasopresinas/metabolismo , Glándulas Sudoríparas/metabolismo , Sudoración , Vasopresinas/metabolismo , Equilibrio Hidroelectrolítico , Adulto , Antagonistas de los Receptores de Hormonas Antidiuréticas , Benzazepinas/administración & dosificación , Biomarcadores/sangre , Biomarcadores/orina , Desamino Arginina Vasopresina/administración & dosificación , Método Doble Ciego , Femenino , Antagonistas de Hormonas/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Neurofisinas/antagonistas & inhibidores , Concentración Osmolar , Resistencia Física/efectos de los fármacos , Volumen Plasmático , Precursores de Proteínas/antagonistas & inhibidores , Carrera , Transducción de Señal , Sodio/sangre , Sodio/orina , Sudor/metabolismo , Glándulas Sudoríparas/efectos de los fármacos , Sudoración/efectos de los fármacos , Sed , Factores de Tiempo , Tolvaptán , Vasopresinas/antagonistas & inhibidores , Equilibrio Hidroelectrolítico/efectos de los fármacos , Pérdida de Peso , Adulto JovenRESUMEN
Free radicals are essential for the vasopressin (AVP) response to plasmatic hyperosmolarity. Noradrenergic afferents are the major projections on the supraoptic nucleus (SON) of the hypothalamus and stimulate the expression of AVP via a nitric oxide (NO) pathway. In this study, we investigated the mechanisms linking free radicals and noradrenaline (NA)-induced regulation of AVP. Analysis of Tg8 transgenic mice, invalidated for the monoamine oxidase-A gene and with consequently high levels of brain monoamines and AVP in the SON, showed that free radicals are more abundant in their SON than in that of wild-type mice (WT). Antioxidant superoxide dismutase 1 and 2 and catalase enzyme activities were also higher in these mice than in WT. This may explain the observed absence of cytotoxicity that would otherwise be associated with such high level of free radicals. Treatment of Tg8 mice with α-MPT, a blocking agent for NA synthesis, decreased both the production of free radicals and the AVP levels in the SON. Furthermore, incubation of ex vivo slices including the SON with NA increased the production of free radicals and AVP levels in wild-type mice. When NA was associated with α-lipoic acid, an antioxidant blocking the production of free radicals, AVP remained at its control level, indicating that free radicals are required for the effect of NA on the expression of AVP. In slices incubated with SNP, a producer of NO, free radicals and AVP levels increased. When NA was associated with L-NAME (a NO synthase blocker), the levels of free radicals and AVP were the same as in controls. Thus, the noradrenaline-NO pathway, which stimulates the expression of vasopressin, involves free radicals. This study provides further evidence of the physiological importance of free radicals, which should no longer be considered solely as cytotoxic factors.
Asunto(s)
Óxido Nítrico/metabolismo , Norepinefrina/metabolismo , Núcleo Supraóptico/metabolismo , Vasopresinas/metabolismo , Animales , Catalasa/metabolismo , Radicales Libres/agonistas , Radicales Libres/antagonistas & inhibidores , Radicales Libres/metabolismo , Expresión Génica , Masculino , Metiltirosinas/farmacología , Ratones , Ratones Endogámicos C3H , Ratones Transgénicos , NG-Nitroarginina Metil Éster/farmacología , Nitroprusiato/farmacología , Norepinefrina/agonistas , Norepinefrina/antagonistas & inhibidores , Transducción de Señal , Superóxido Dismutasa/metabolismo , Superóxido Dismutasa-1 , Núcleo Supraóptico/efectos de los fármacos , Ácido Tióctico/farmacología , Técnicas de Cultivo de Tejidos , Vasopresinas/agonistas , Vasopresinas/antagonistas & inhibidores , Vasopresinas/genéticaRESUMEN
BACKGROUND: Research concerning non-reproductive sociability in rodents is mainly restricted to assessing the effects of oxytocin (OXT) and arginine-vasopressin (AVP) in male rats and mice. Comparable studies on natural social preference and social avoidance in females are substantially lacking. NEW METHOD: Here, we adapted a behavioral paradigm for monitoring social preference of female rats consisting of two consecutive exposures to either non-social or social stimuli. Further, to induce stimulus-specific social avoidance, female rats were exposed to a single 10-min maternal defeat by a lactating dam. RESULTS: Social preference towards same-sex conspecifics in female rats was shown to be independent of the estrous cycle and even more pronounced than in male rats. Intracerebroventricular (icv) application of OXT, AVP, or their selective receptor antagonists or agonists, did not alter naturally-occurring social preference in female rats. Stimulus-specific social avoidance could be induced by prior exposure to a lactating rat: an effect that could not be reversed/overcome by icv OXT. COMPARISON WITH EXISTING METHOD(S): The female social preference paradigm for rats established in this study detected subtle sex differences in social preference behavior of rats. Further, stimulus-specific social deficits could be induced in female rats using an acute exposure to social defeat - as previously observed in male rodents. CONCLUSIONS: Female rats show strong social preference behavior, which can be prevented by social defeat, but does not seem to be regulated by the OXT or AVP systems. Accordingly, icv application of synthetic OXT does not reverse maternal defeat-induced social avoidance in female rats.
Asunto(s)
Encéfalo/metabolismo , Reacción de Fuga/fisiología , Oxitocina/metabolismo , Caracteres Sexuales , Estrés Psicológico , Vasopresinas/metabolismo , Análisis de Varianza , Animales , Arginina Vasopresina/análogos & derivados , Arginina Vasopresina/farmacología , Modelos Animales de Enfermedad , Ciclo Estral , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Regulación de la Expresión Génica/fisiología , Masculino , Ornipresina/análogos & derivados , Ornipresina/farmacología , Oxitocina/antagonistas & inhibidores , Oxitocina/farmacología , Ratas , Ratas Wistar , Conducta Social , Estrés Psicológico/metabolismo , Estrés Psicológico/patología , Estrés Psicológico/psicología , Vasopresinas/antagonistas & inhibidores , Vasopresinas/farmacologíaRESUMEN
Anaphylactic shock is sometimes life-threatening, but the defense system against this circulatory failure was not fully understood. Ameliorating roles of angiotensin (ANG) II and vasopressin in anaphylactic hypotension were investigated in anesthetized ovalbumin-sensitized Sprague-Dawley rats. The sensitized rats were randomly allocated to the following pretreatment groups (n=7/group): (1) control (non-pretreatment), (2) ANG II synthesis inhibitor captopril, (3) ANG II receptor antagonist losartan, and (4) V1a vasopressin receptor antagonist. Anaphylactic shock was induced by an intravenous injection of the antigen. The systemic arterial pressure (SAP), central venous pressure (CVP), portal venous pressure (PVP) and portal venous blood flow (PBF) were measured, and splanchnic vascular resistance (Rspl: (SAP-PVP)/PBF) was determined. In the control group, SAP markedly decreased, followed by a gradual recovery toward baseline. Rspl transiently decreased immediately after antigen, and then increased 1.5-fold at 15 min and thereafter. The pretreatment with either losartan, captopril or V1a receptor antagonist augmented the initial fall of SAP and attenuated the SAP recovery along with augmentation of the late increase in Rspl. The 2-h survival rate was significantly smaller in either pretreatment group than in the control group (100%). Plasma levels of ANG II and vasopressin increased to 3.8- and 9.8-fold, respectively, at 30 min after antigen in the control group, whereas captopril pretreatment inhibited the increase in ANG II. In conclusion, inhibition of ANG II or vasopressin exacerbates anaphylaxis-induced hypotension in anesthetized rats.